Advances in blood-brain barrier modeling in microphysiological systems highlight critical differences in opioid transport due to cortisol exposure

被引:29
|
作者
Brown, Jacquelyn A. [1 ]
Faley, Shannon L. [1 ,2 ]
Shi, Yajuan [3 ]
Hillgren, Kathleen M. [4 ,5 ]
Sawada, Geri A. [4 ,5 ]
Baker, Thomas K. [4 ,5 ]
Wikswo, John P. [1 ,2 ,6 ,7 ]
Lippmann, Ethan S. [2 ,3 ,8 ]
机构
[1] Vanderbilt Univ, Vanderbilt Inst Integrated Biosyst Res & Educ, 221 Kirkland Hall, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA
[3] Vanderbilt Univ, Dept Chem & Biomol Engn, Nashville, TN 37235 USA
[4] Eli Lilly & Co, Dept ADME, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Dept Toxicol, Indianapolis, IN 46285 USA
[6] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA
[7] Vanderbilt Univ, Dept Phys, Nashville, TN 37235 USA
[8] Vanderbilt Univ, Vanderbilt Brain Inst, 221 Kirkland Hall, Nashville, TN 37235 USA
基金
美国国家卫生研究院;
关键词
P-GLYCOPROTEIN; ENDOTHELIAL-CELLS; RAT; DRUGS; PHARMACOKINETICS; DEXAMETHASONE; LOCALIZATION; LOPERAMIDE; OXYCODONE; HEALTH;
D O I
10.1186/s12987-020-00200-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background The United States faces a national crisis involving opioid medications, where currently more than 130 people die every day. To combat this epidemic, a better understanding is needed of how opioids penetrate into the central nervous system (CNS) to facilitate pain relief and, potentially, result in addiction and/or misuse. Animal models, however, are a poor predictor of blood-brain barrier (BBB) transport and CNS drug penetration in humans, and many traditional 2D cell culture models of the BBB and neurovascular unit have inadequate barrier function and weak or inappropriate efflux transporter expression. Here, we sought to better understand opioid transport mechanisms using a simplified microfluidic neurovascular unit (NVU) model consisting of human brain microvascular endothelial cells (BMECs) co-cultured with astrocytes. Methods Human primary and induced pluripotent stem cell (iPSC)-derived BMECs were incorporated into a microfluidic NVU model with several technical improvements over our previous design. Passive barrier function was assessed by permeability of fluorescent dextrans with varying sizes, and P-glycoprotein function was assessed by rhodamine permeability in the presence or absence of inhibitors; quantification was performed with a fluorescent plate reader. Loperamide, morphine, and oxycodone permeability was assessed in the presence or absence of P-glycoprotein inhibitors and cortisol; quantification was performed with mass spectrometry. Results We first report technical and methodological optimizations to our previously described microfluidic model using primary human BMECs, which results in accelerated barrier formation, decreased variability, and reduced passive permeability relative to Transwell models. We then demonstrate proper transport and efflux of loperamide, morphine, and oxycodone in the microfluidic NVU containing BMECs derived from human iPSCs. We further demonstrate that cortisol can alter permeability of loperamide and morphine in a divergent manner. Conclusions We reveal a novel role for the stress hormone cortisol in modulating the transport of opioids across the BBB, which could contribute to their abuse or overdose. Our updated BBB model represents a powerful tool available to researchers, clinicians, and drug manufacturers for understanding the mechanisms by which opioids access the CNS.
引用
收藏
页数:12
相关论文
共 18 条
  • [11] 2,4,6-Tribromophenol Exposure Decreases P-Glycoprotein Transport at the Blood-Brain Barrier
    Trexler, Andrew W.
    Knudsen, Gabriel A.
    Nicklisch, Sascha C. T.
    Birnbaum, Linda S.
    Cannon, Ronald E.
    TOXICOLOGICAL SCIENCES, 2019, 171 (02) : 463 - 472
  • [12] Can P-glycoprotein expression on malignant tumor tissues predict opioid transport at the blood-brain barrier in cancer patients?
    Bruno Mégarbane
    Hisham Alhaddad
    Pharmacological Reports, 2013, 65 : 235 - 236
  • [13] Possible involvement of cationic-drug sensitive transport systems in the blood-to-brain influx and brain-to-blood efflux of amantadine across the blood-brain barrier
    Suzuki, Toyofumi
    Fukami, Toshiro
    Tomono, Kazuo
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (02) : 126 - 137
  • [14] Can P-glycoprotein expression on malignant tumor tissues predict opioid transport at the blood-brain barrier in cancer patients?
    Megarbane, Bruno
    Alhaddad, Hisham
    PHARMACOLOGICAL REPORTS, 2013, 65 (01) : 235 - 236
  • [15] Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting
    Fabre, Kristin M.
    Delsing, Louise
    Hicks, Ryan
    Colclough, Nicola
    Crowther, Damian C.
    Ewart, Lorna
    ADVANCED DRUG DELIVERY REVIEWS, 2019, 140 (129-135) : 129 - 135
  • [16] Differences in amyloid-β clearance across mouse and human blood-brain barrier models: Kinetic analysis and mechanistic modeling
    Qosa, Hisham
    Abuasal, Bilal S.
    Romero, Ignacio A.
    Weksler, Babette
    Couraud, Pierre-Oliver
    Keller, Jeffrey N.
    Kaddoumi, Amal
    NEUROPHARMACOLOGY, 2014, 79 : 668 - 678
  • [17] Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model
    Navarro, C.
    Gonzalez-Alvarez, I.
    Gonzalez-Alvarez, M.
    Manku, M.
    Merino, V.
    Casabo, V. G.
    Bermejo, M.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 42 (03) : 290 - 299
  • [18] Gene expression of fatty acid transport and binding proteins in the blood-brain barrier and the cerebral cortex of the rat: Differences across development and with different DHA brain status
    Pelerin, Helene
    Jouin, Melanie
    Lallemand, Marie-Sylvie
    Alessandri, Jean-Marc
    Cunnane, Stephen C.
    Langelier, Benedicte
    Guesnet, Philippe
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2014, 91 (05): : 213 - 220